Naloxone Switch: Door Opener For Other NDAs That Swing On Consumer Education
This article was originally published in The Tan Sheet
Executive Summary
Health care professionals provide naloxone in an outpatient setting in “highly successful programs,” but FDA approval of a switch rests on whether “just putting the drug on the store shelf for anyone to purchase with no training or guidance on use” will be safe, says nonprescription drug division head Theresa Michele.
You may also be interested in...
OTC Homeopathic Labels Must Include Scientific Disclaimers – FTC
US trade regulator will require an "inherent contradiction" for homeopathic OTC labels: disclaimers to FDA-compliant label indications indicating a lack of scientific evidence that the product works.
OTC Homeopathic Labels Must Include Scientific Disclaimers – FTC
US trade regulator will require an "inherent contradiction" for homeopathic OTC labels: disclaimers to FDA-compliant label indications indicating a lack of scientific evidence that the product works.
Rescue Medicine Switch Concept Draws Criticism
FDA considers switching some prescription “antidotes” to restricted nonprescription status so consumers who can self-identify their need for the drugs and who previously had a prescription can easily access them during life-threatening events, says CDER Director Janet Woodcock.